Cartesian Therapeutics focuses on RNA-based cell therapies. In August, for example, the company announced successful results from a Phase I trial of an RNA-based treatment called Descartes-08 for the autoimmune disorder myasthenia gravis. Murat Kalayoglu, MD, PhD, president and CEO describes this treatment as “an autologous T-cell product engineered with RNA to express a chimeric […]

To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and industry to give us their reflections, impressions, and insights on the biotechnology industry and the life sciences. We also queried them on what they believe the future might look like for biotechnology. We sought the thoughts […]

Current standard-of-care procedures used to treat complex and chronic wounds are often highly invasive, with low efficiencies and high complication rates. To address the significant unmet medical needs in chronic wound treatment, PolarityTE is developing a range of regenerative tissue products utilizing a patient’s own cells and tissues, such as SkinTE®. Technology Networks recently spoke […]